Tegileridine, a newly developed G protein-biased mu-opioid receptor agonist, provides effective analgesia compared to placebo for patients recovering from major surgery, but its clinical superiority or equivalence to established opioids remains unproven across diverse surgical settings. A structured narrative review published in Frontiers in Pharmacology by researchers from Gannan Medical University examined human clinical evidence and pharmacological data published through October 9, 2026. The drug was initially approved in China in January 2024 for moderate-to-severe postoperative pain following abdominal surgery, followed by an additional indication in March 2025 for pain following orthopedic procedures. While modern pain therapeutics have sought to uncouple analgesic signaling from life-threatening side effects, clinical investigations indicate that translating pathway bias into definitive clinical advantages remains a complex and ongoing challenge.
Acute postoperative discomfort affects a substantial portion of surgical patients, with studies indicating that approximately 80 percent experience moderate-to-severe pain and up to 32.2 percent encounter severe pain. Inadequately controlled acute pain not only impairs functional recovery and increases complication risks, but severity and duration of acute surgical pain also serve as primary predictors for the development of chronic postsurgical pain. Traditional opioids remain the standard therapeutic choice for moderate-to-severe surgical discomfort, yet their therapeutic utility is frequently restricted by opioid-related adverse events such as respiratory depression, postoperative nausea, vomiting, constipation, tolerance, and addiction potential. Consequently, drug developers designed G protein-biased mu-opioid receptor agonists under the hypothesis that promoting G protein signaling while minimizing beta-arrestin-2 recruitment would preserve analgesia while diminishing adverse effects.
The biological rationale for pathway selectivity centers on the dual intracellular cascades triggered when conventional agonists bind to the Gi-protein-coupled mu-opioid receptor. Downstream G protein signaling mediates analgesia through adenylyl cyclase inhibition, cyclic adenosine monophosphate reduction, and neuronal hyperpolarization via inwardly rectifying potassium channels. In contrast, receptor phosphorylation recruits beta-arrestin-2, driving receptor internalization, desensitization, and downstream kinase activation that historically was presumed responsible for adverse sequelae. However, contemporary pharmacological investigations have challenged this dichotomy, suggesting that respiratory depression involves widespread activation of potassium channels in brainstem respiratory centers, while opioid-induced emesis is partly mediated through G-protein pathways in the vestibular system and chemoreceptor trigger zone. Furthermore, alternative hypotheses argue that observed side-effect improvements in biased molecules might stem from lower intrinsic efficacy or partial agonism rather than genuine signaling bias.
In human pharmacokinetic evaluations, intravenous tegileridine demonstrates rapid onset and a distinct metabolic route compared with conventional analgesics and earlier biased agonists. Following intravenous administration, effective plasma concentrations are established within approximately 5 minutes, exhibiting an elimination half-life of 6 to 7 hours. This half-life is notably longer than that of oliceridine, which ranges from 1.3 to 3.7 hours, and also exceeds the typical elimination half-lives of sufentanil, fentanyl, and immediate-release oxycodone. Tegileridine is exclusively cleared through esterase-mediated hydrolysis rather than cytochrome P450 pathways, generating no active metabolites and significantly reducing the risk of CYP450-mediated drug-drug interactions. Nonetheless, clinical pharmacologists note that esterase activity can vary with severe hepatic impairment, genetic polymorphisms, or interacting medications, warranting dedicated investigations in vulnerable populations.
The primary clinical evidence supporting tegileridine derives from a multicenter, randomized, double-blind Phase III trial involving 526 abdominal surgery patients across 48 medical centers in China. Participants experiencing moderate-to-severe resting pain were randomized to receive placebo, morphine at a 3.0 milligram loading dose, or tegileridine at loading doses of 0.75 milligrams or 1.0 milligram, followed by patient-controlled intravenous analgesia. Both tegileridine arms demonstrated statistically significant superiority over placebo for the primary endpoint of 24-hour summed pain intensity difference. The mean 24-hour score was negative 61.15 in the 0.75 milligram arm and negative 68.98 in the 1.0 milligram arm, compared to negative 49.63 with placebo. The proportion of patients avoiding rescue analgesia within 24 hours reached 72.9 percent and 78.6 percent in the tegileridine cohorts, respectively, significantly outperforming the 40.8 percent rescue-free rate recorded in the placebo control group.
Despite clear superiority over placebo, the Phase III trial did not establish equivalence or non-inferiority between tegileridine and morphine. Although the 24-hour summed pain intensity difference for tegileridine 1.0 milligram was numerically close to the negative 71.16 observed with morphine, the study protocol lacked a formal non-inferiority or equivalence hypothesis test. Secondary measures including 6-hour, 12-hour, and 18-hour pain difference scores, as well as 24-hour total pain relief, demonstrated comparable numerical values between the 1.0 milligram dose and morphine, while rescue-free rates remained comparable at 78.6 percent and 72.7 percent. A post hoc observation noted higher proportions of patients achieving mild pain scores within two hours of dosing with tegileridine, but the absence of formal statistical testing renders this finding hypothesis-generating rather than confirmatory.
Beyond the Phase III trial, randomized comparisons with other opioids have yielded mixed findings that complicate direct therapeutic comparisons. A 2026 meta-analysis of randomized controlled trials reported that 24-hour resting summed pain intensity differences significantly favored morphine over tegileridine, despite finding no significant difference at 12 hours. Conversely, a single-center, double-blind randomized trial of 120 general surgery patients evaluated patient-controlled intravenous analgesia using 5 milligrams of tegileridine versus 200 micrograms of sufentanil. The study demonstrated that tegileridine met its prespecified non-inferiority margin for the 24-hour resting pain area-under-the-curve outcome while reporting lower rates of postoperative nausea and vomiting. However, because trial designs, dosing ratios, surgical trauma levels, and primary endpoints differed considerably between investigations, findings cannot be generalized across opioid classes.
Safety data across surgical cohorts demonstrate acceptable general tolerability but illustrate that side-effect reductions are inconsistent and heavily context-dependent. In the Phase III abdominal surgery trial, overall treatment-emergent adverse events occurred in 77.3 percent of patients in the 0.75 milligram tegileridine group and 77.9 percent in the 1.0 milligram group, closely matching rates of 75.0 percent for morphine and 74.0 percent for placebo. Most documented adverse events were mild or moderate. Nausea rates were 22.0 percent with 0.75 milligrams and 19.1 percent with 1.0 milligram of tegileridine compared to 24.2 percent with morphine, while vomiting occurred in 23.5 percent and 22.1 percent versus 28.8 percent, respectively. Although antiemetic utilization was numerically lower in tegileridine groups at 25.9 percent compared to 32.6 percent with morphine, these differences did not achieve statistical significance.
More pronounced side-effect reductions emerged in specialized, single-center surgical trials where baseline risks or delivery methods differed. In a randomized trial of 68 women undergoing total laparoscopic hysterectomy, a single intravenous bolus of 0.01 milligrams per kilogram of tegileridine produced comparable post-anesthesia analgesia success rates to 0.06 milligrams per kilogram of oxycodone, but significantly decreased postoperative nausea and vomiting from 54.3 percent to 27.3 percent. Similarly, in a trial of 72 patients undergoing laparoscopic sleeve gastrectomy, tegileridine patient-controlled analgesia yielded higher 24-hour Quality of Recovery scores and lower nausea and vomiting rates than sufentanil. However, the observed 5-point recovery score improvement remained below the established minimal clinically important difference threshold of 8 points, leaving its clinical relevance open to question.
Respiratory safety evaluations also highlight the preliminary nature of existing clinical comparisons across different surgical populations. In the Phase III abdominal surgery trial, respiratory depression was exceptionally rare, with only one patient in the 0.75 milligram group experiencing a transient oxygen desaturation to 89 percent that resolved without intervention within 4 minutes. In an exploratory dose-finding hysteroscopy study of 54 patients, tegileridine demonstrated a median effective dose of 23.22 micrograms per kilogram for suppressing the cervical dilation reflex, compared to 1.51 micrograms per kilogram for fentanyl, yielding a potency ratio of 15.4 to 1. While the hysteroscopy study recorded a significantly lower incidence of desaturation with tegileridine than fentanyl, the investigation employed an open-label design, varying administration techniques, and a sensitive desaturation threshold of 92 percent with prophylactic oxygen permitted.
Critical therapeutic questions also persist regarding long-term physiological consequences, equianalgesic dosing accuracy, and addiction vulnerability. Early theoretical assumptions that signaling pathway bias could eliminate physical dependence or misuse potential remain entirely unsubstantiated by human empirical data. The reviewed studies lacked systematic evaluations of tolerance, opioid-induced hyperalgesia, endocrine alterations, sleep-disordered breathing, electrocardiographic QT intervals, and formal human abuse liability. Furthermore, comparative safety conclusions are vulnerable to confounding from equianalgesic dose mismatches, as validated conversion ratios between tegileridine and traditional opioids have not been systematically established across diverse surgical contexts.
Current evidence confirms that tegileridine is an active postoperative analgesic that reliably surpasses placebo in acute surgical settings, but its definitive clinical standing relative to conventional opioids awaits rigorous validation. Ongoing prospective investigations, including randomized trials in elderly cancer patients and thoracic surgery cohorts, are positioned to address existing demographic and procedural evidence gaps. Until large-scale, multicenter trials confirm sustained improvements in patient recovery, validated equianalgesic dosing, and real-world safety outcomes, tegileridine represents a pharmacologically distinct therapeutic alternative whose purported clinical advantages remain selectively observed rather than broadly established.
Subject of Research: Clinical evidence and pharmacology of tegileridine for postoperative pain management
Article Title: Clinical evidence on tegileridine, a G protein-biased μ-opioid receptor agonist, for postoperative pain management: a structured narrative review
Article References: Wang, Y., Han, R., Yang, X., Zhang, X., Deng, Z., Xia, L., & Zhong, M.-L. (2026). Clinical evidence on tegileridine, a G protein-biased μ-opioid receptor agonist, for postoperative pain management: a structured narrative review. Frontiers in Pharmacology, 17, Article 1938782. https://doi.org/10.3389/fphar.2026.1938782
Image Credits: AI Generated
DOI: 10.3389/fphar.2026.1938782
Keywords: tegileridine, SHR8554, biased opioid agonist, mu-opioid receptor, postoperative pain, analgesia, patient-controlled intravenous analgesia, morphine, sufentanil, oliceridine, postoperative nausea and vomiting, respiratory depression, abdominal surgery, orthopedic surgery, clinical trials, pharmacokinetics
News Source: Ophelia Keating. (November 18, 2026). Tegileridine Demonstrates Postoperative Pain Relief While Comparative Benefits Remain Unresolved. Scienmag.



